Skip to main content
Premium Trial:

Request an Annual Quote

Atugen, Byk Gulden Strike Cancer Target Collaboration

NEW YORK, Nov. 19 — German genomics firm atugen has signed an evaluation agreement with countrymate Byk Gulden, the company said on Monday


Under the agreement, Byk Gulden, based in Constance, will provide atugen with cancer-associated genetic targets in specific cell lines. Berlin-based atugen will in turn identify biological function of the targets and validate them for potential drug development.


Financial details of the agreement were not disclosed.


Atugen is focused on high throughput target analysis and validation of pharmaceutical targets. Its GeneBloc technology works by inducing small DNA/RNA hybrid molecules to bind to and destroy target mRNA. This specific mRNA loss can then be correlated with functional changes in vivo and in cell-based assays, leading to an understanding of gene function.


Byk Gulden, the pharmaceutical division of ALTANA, specializes in therapeutics for gastrointestinal, respiratory tract, and cardiovascular conditions.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.